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Controversy of calcium antagonists: is there a rational differential
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Cardiology, University Hospital/Inselspital, Bern, Switzerland
Calcium antagonists are among the most frequently
used medications, particularly for the treatment of
hypertension and coronary heart disease. Three classes
of calcium antagonists can be differentiated, namely
(i) dyhydropyridine (e.g. nifedipine, etc.), (ii) verapa-
mil, and (iii) diltiazem. All calcium antagonists are
potent vasodilators. First generation dihydropyridine
increases the heart rate while verapamil and diltiazem
decrease or do not alter the heart rate. The new
dihydropyridines do not or only mildly influence heart
rate. Although they are efficacious in decreasing blood
pressure and have anti-anginal effects, their safety,
especially in terms of their effects on the survival of
patients with coronary heart disease and those with
hypertension, has been questioned in recent publica-
tions. A meta-analysis by Curt Furberg found that
patients with coronary heart disease treated with short
acting nifedipine had a dose dependent increase in
mortality compared to the control group. This negative
effect has only been found at very high doses of 60 mg
and higher. In this meta-analysis, studies were included
which investigated the effects of short acting nifedipine
and mortality and morbidity were not necessarily used
as endpoints in all the strains.
Recently, two case controlled studies on hypertensive
patients were published. They showed that patients
treated with short acting nifedipine had a higher rate
of myocardial infarction than those treated with /?-
blockers. These results and the reports in the media
have made physicians in clinic and practice, as well as
their patients extremely insecure.
Calcium antagonists have an anti-hypertensive and
anti-anginal effect and probably also have anti-
atherosclerosis properties. Prospective, randomized
studies regarding the effects on mortality and morbidity
such as those carried out in the 70's and 80's for /?-
blockers, diuretics and older antihypertensives, are
lacking for calcium antagonists (as well as for ACE-
inhibitors) in patients with hypertension and stable
angina pectoris. The STONE study in China at least
indicated that hypertensive patients administered nifed-
ipine had a decrease in the frequency of cerebral stroke.
Less can be said regarding coronary heart disease since
the prevalence of this disease is so low in this Asian
population. Nevertheless, the results of the retrospect-
ive case controlled studies in hypertensive patients
should certainly be taken seriously, even though they
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can not be considered as having resolved the issue.
One must bear in mind that the patients in these case
controlled studies were mostly treated with short acting
nifedipine, i.e. pharmacological preparations which are
hardly used any more in Europe since the introduction
of slow release preparations and long acting calcium
antagonists. The effects of calcium antagonists on
coronary heart disease in patients with hypertension
remains still undetermined. This question will be
answered in a few years by the ongoing ALLHAT
study and INSIGHT study.
The anti-anginal effect of these substances in patients
with stable angina pectoris is uncontested. The APSIS
study proved that similar survival rates are obtained
with verapamil as with the /?-blocker, metoprolol.
Similar results were obtained for slow releasing nifedip-
ine and atenolol in the TIBET study.
Short acting preparations, especially those which
stimulate the sympathetic system and, therefore,
increase the heart rate, should not be used, or only
together with a /?-blocker, in patients with coronary
heart disease. In patients with vasospastic angina pec-
toris, calcium antagonists, especially nifedipine, are the
first choice.
Studies with first generation calcium antagonists do
not show any positive effect on mortality in patients
with unstable angina or acute myocardial infarction.
Accordingly, their use for this indication should be
considered with great reservation and they should only
be used for symptomatic treatment and only after
previous beta blockade (to diminish sympathetic
activation) in specially selected cases.
For secondary prevention after myocardial infarc-
tion, verapamil and diltiazem appear to have a moder-
ately favorable effect only in patients without
congestive heart failure. It should be noted that the
secondary prevention effects of cholesterol lowering
drugs and aspirin in this patient group is at least as
important. In coronary patients with heart failure,
neither verapamil nor amilodipine nor felodipine had
a favorable effect on survival, while diltiazem was even
associated with an increase in death rate. Therefore,
verapamil, amlodipine and felodipine should only be
administered when symptoms are present (ischaemia
or angina pectoris) and only to patients who are not
candidates for a bypass operation or PTCA.
Presently, it appears worthwhile to use the potential
of calcium antagonists and to decrease possible risks
in patients with cardiovascular diseases by the use of
a differential therapy. It should be especially noted
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that not all calcium antagonists are the same and
depending on the diagnosis and type of therapeutic
indication, i.e. symptomatic or preventive, an individu-
alized differential therapy must be considered (Fig. 1).
For hypertension and stable angina pectoris, calcium
antagonists are effective and still may be used.
However, short acting dihydropyridines should be
definitely avoided. Until the results of prospective
studies are available, calcium antagonists should be
discontinued and replaced by other antihypertensive
drugs before major surgery due to the increased risk
of hemorrhage. In patients with unstable angina, cal-
cium antagonists should not be used, or only after
administration of/?-blockers. They are not appropriate
in acute myocardial infarction. For secondary preven-
tion after myocardial infarction, calcium antagonists
are not the first choice and should only be used when
adequate left ventricular function is present. Aspirin,
/?-blockers, ACE inhibitors and cholesterol reducing
drugs should be given preference for this indication.
In patients with compromised left ventricular function
and heart failure, verapamil, amlodipine and felodipine
should be administered only to treat symptoms and
not for secondary prevention. In this indication, they
should only be considered in patients who are already
treated with an ACE inhibitor, diuretic and digitalis
and in those in which invasive therapy such as PTCA
or bypass for the treatment of ischemia is not possible.
In hypertrophic cardiomyopathy or supraventricular
arrythmias, phenylakylamine calcium antagonists (ver-
apamil) or those of the benzothiazepine group (diltia-
zem) are appropriate as selected first like drugs
(Fig. 1).
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Fig. 1. Differential use of calcium antagonists in patients with cardio-
vascular disease.
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